Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 176, Issue 1-2, Pages 187-197Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2006.04.011
Keywords
myasthenia gravis (MG); experimental autoimmune myasthenia gravis (EAMG); intravenous immunoglobulins (IVIG); immunomodulation
Categories
Ask authors/readers for more resources
Intravenous immunoglobulin (IVIG) administration has been beneficially used in the treatment of several autoimmune disorders including myasthenia gravis (MG), although its mechanism of action is still not clear. To study the optimal conditions of IVIG treatment and delineate its mechanism of action we established a suitable model in rat experimental autoimmune MG (EAMG). We show that IVIG has a suppressive effect on the clinical symptoms of ongoing EAMG that is associated with decreased AChR-specific cellular and humoral immune reactivity. Costimulatory factors and cytokine profile analyses suggest that IVIG immunomodulation in EAMG involves suppression of B and Th1-type T cell responses with no generation of T-regulatory cells. Our data contribute to the understanding of the immunological mechanisms underlying IVIG treatment in MG and in other autoimmune disorders. (c) 2006 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available